check quantity

AlphaLISA SureFire Ultra Human Phospho-c-Myb (Ser11) Detection Kit, 500 Assay Points

The AlphaLISA® SureFire® Ultra Human Phospho-c-Myb (Ser11) assay is a sandwich immunoassay for quantitative detection of phospho-c-Myb (Ser11) in cellular lysates using Alpha Technology.

For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

Part Number
Unit Size
List Price
Your Price
500 Assay Points
1979.00 USD
10,000 Assay Points
12100.00 USD
50,000 Assay Points
38800.00 USD
100 Assay Points
589.00 USD
Buy Now

Please enter valid quantity

Please log in to add favorites.



Mammalian oncogenic transcription factor c-Myb is a member of the MYB family of proteins, encoded by the C-MYB gene, which is located in chromosome 6. The family received its name because of its association with myeloblastosis, taking the letters ‘m’, ‘y’ and ‘b’ from this word to create the family name. C-myb controls several genes related to cell proliferation, differentiation, and apoptosis. Sustained and high levels of MYB expression are seen in leukemia, colon cancer, breast cancer, and adenoid cystic carcinoma.

The AlphaLISA SureFire Ultra Human Phospho-c-Myb (Ser11) Detection Kit is a sandwich immunoassay for the quantitative detection of phospho-c-Myb (Ser11) in cellular lysates, using Alpha Technology.


  • The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
  • The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
  • The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
  • The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

  • Cell and tissue lysates
  • Antibody modulators
  • Biotherapeutic antibodies

Alpha SureFire kits can be used for:

  • Cellular kinase assays
  • Receptor activation studies
  • Screening


Assay Points (200-50,000) 500 Assay Points
Assay Target c-Myb
Assay Technology Alpha
Automation Compatible Yes
Detection Method Alpha
Experimental Type In vitro
Product Brand Name AlphaLISA SureFire Ultra
Shipping Condition Blue Ice
Target Species Human
Therapeutic Area Oncology
Unit Size 500 Assay Points
Resources, Events & More
  • All

Application Brief

Eight Limitations of ELISA and How to Overcome Them Using Alternative Technologies

The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.

Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.



Alpha Technology Solutions

Product brochure for the Alpha Technology, a versatile, no wash, homogeneous assay technology that's suitable for a broad range of applications.

Drug Discovery Screening Solutions Brochure

Find out about our range of integrated solutions for drug discovery screening in this e-brochure.

Our screening solutions for high-throughput screening, phenotypic screening and data analysis help to streamline drug discovery workflows in labs across the globe. Our portfolio includes automated liquid handling, assays and reagents, imaging and detection systems, and informatics.

Working independently or together, with our solutions you can achieve consistent and accurate results. By accelerating the identification and characterization of effective and safe drug candidates, the PerkinElmer portfolio enables you to optimize efficiency in your lab and deliver more actionable, real-world results.

Download the brochure to learn more about how we can partner with you so that you can discover smarter, more effective, data-driven breakthroughs in the critical screening stages of drug discovery and development.